Cutaneous Amyloidosis: An Updated Approach Focusing on Macular Amyloidosis.

BACKGROUND

Amyloidosis is formed following deposition of protein aggregates and is classified by systemic or cutaneous deposition.

SUMMARY: These aggregates can be distributed in different organs such as the heart, liver, lungs, kidneys, and skin. Primary cutaneous amyloidosis has been classified into three groups: macular, lichen, and nodular, the former two being one often overlapping process, and the latter a localized plasma dyscrasia with a small risk of representing a systemic disease.

KEY MESSAGES: Historically, cutaneous amyloidosis has been misdiagnosed, and most treatment regimens have been ineffective or only provide supportive management, such as decreasing pruritus. The current standard of care, high-potency corticosteroids, can provide symptomatic relief. Newer therapies may decrease amyloid deposition and progression of disease.